Abstract
The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1004-1009 |
| Number of pages | 6 |
| Journal | Journal of Urology |
| Volume | 144 |
| Issue number | 4 |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Dipyramidole-cisplatin potentiation : Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. / Keane, T. E.; Rosner, Gary; Donaldson, J. T.; Norwood, D. L.; Poulton, S. H.; Walther, P. J.
In: Journal of Urology, Vol. 144, No. 4, 1990, p. 1004-1009.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dipyramidole-cisplatin potentiation
T2 - Enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers
AU - Keane, T. E.
AU - Rosner, Gary
AU - Donaldson, J. T.
AU - Norwood, D. L.
AU - Poulton, S. H.
AU - Walther, P. J.
PY - 1990
Y1 - 1990
N2 - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.
AB - The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model. Single agent post treatment tumor volume growth ratio [TGR] values of DP, MTX and CDDP were 97%, 65% and 49% of control. While the MTX/DP combination produced only mild cytotoxic enhancement, CDDP/DP and CDDP/MTX/DP reduced TGR to 20% and 17%, respectively. A second multi-dose evaluation of CDDP/DP using human testicular carcinoma in this model also showed a CDDP dose-dependent response with achievable complete tumor regression. Host toxicity was not substantially increased by DP. DP would appear to be effective in vivo as a chemosensitizer of CDDP; it may enhance the therapeutic efficacy of CDDP in a variety of tumors.
UR - http://www.scopus.com/inward/record.url?scp=0025194067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025194067&partnerID=8YFLogxK
M3 - Article
C2 - 2398547
AN - SCOPUS:0025194067
VL - 144
SP - 1004
EP - 1009
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 4
ER -